1 of 1
Story summary
- A study in Lancet Gastroenterology & Hepatology projects metabolic dysfunction-associated steatotic liver disease (MASLD) will affect 1.8 billion people globally by 2050, up from 1.3 billion in 2023.
- The condition is linked to obesity and high blood sugar, and its prevalence has risen about 143% over the past 30 years.
- Although treatments extend life, many remain at risk for cirrhosis; the study calls for awareness and interventions for younger adults.
